Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements

Mikolasevic, I.; Lukenda Zanko, V.; Jakopcic, I.; Domislovic, V.; Mijic, A.; Stevanovic, T.; Delija, B.; Bokun, T.; Dinjar Kujundzic, P.; Ostojic, A.; Filipec Kanizaj, T.; Grgurevic, I.; Krznaric, Z.; Stimac, D.; Targher, G.

doi:10.1016/j.jdiacomp.2019.107512

Pregled bibliografske jedinice broj: 1183127

Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements

Mikolasevic, I.; Lukenda Zanko, V.; Jakopcic, I.; Domislovic, V.; Mijic, A.; Stevanovic, T.; Delija, B.; Bokun, T.; Dinjar Kujundzic, P.; Ostojic, A. et al.

Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements // Journal of diabetes and its complications, 34 (2020), 3; 1-7 doi:10.1016/j.jdiacomp.2019.107512 (recenziran, članak, znanstveni)

CROSBI ID: 1183127 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements

Autori
Mikolasevic, I. ; Lukenda Zanko, V. ; Jakopcic, I. ; Domislovic, V. ; Mijic, A. ; Stevanovic, T. ; Delija, B. ; Bokun, T. ; Dinjar Kujundzic, P. ; Ostojic, A. ; Filipec Kanizaj, T. ; Grgurevic, I. ; Krznaric, Z. ; Stimac, D. ; Targher, G.

Izvornik
Journal of diabetes and its complications (1056-8727) 34 (2020), 3; 1-7

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Controlled attenuation parameter ; Fibroscan ; Liver stiffness measurements ; Nonalcoholic fatty liver disease

Sažetak
Aims: To examine the temporal changes of both controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), assessed by Fibroscan, in a large sample of patients with non- alcoholic fatty liver disease (NAFLD). Methods: In this prospective, observational study, we consecutively enrolled 507 adult individuals with Fibroscan-defined NAFLD who were followed for a mean period of 21.2 ± 11.7 months. Results: During the follow-up period, 84 patients (16.5%) had a progression of CAP of at least 20% with a median time of 39.93 months, while 201 (39.6%) patients had a progression of LSM of at least 20% with median time of 30.46 months. There were significant differences in the proportion of LSM progression across body mass index (BMI) categories, with obese patients having the highest risk of progression over the follow-up (hazard ratio 1.66 ; 95%CI 1.23-2.25). Multivariable regression analysis showed that BMI and serum creatinine levels were the strongest predictors for CAP progression in the whole population, while HOMA-estimated insulin resistance was an independent predictor of LSM progression over time in the subgroup of obese patients. Conclusion: This prospective study shows for the first time that the progression risk of both liver steatosis and fibrosis, detected non-invasively by Fibroscan, is relevant and shares essentially the same metabolic risk factors that are associated with NAFLD progression detected by other invasive methods.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Rijeka

Profili:

Tomislav Bokun (autor)